Matched-pair analysis of $^{[177}\text{Lu}]$Lu-PSMA I&T and $^{[177}\text{Lu}]$Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Philipp E. Hartrampf$^1$ · Franz-Xaver Weinzierl$^1$ · Andreas K. Buck$^1$ · Steven P. Rowe$^2$ · Takahiro Higuchi$^1$ · Anna Katharina Seitz$^3$ · Hubert Kübler$^3$ · Andreas Schirbel$^1$ · Markus Essler$^4$ · Ralph A. Bundschuh$^4$ · Rudolf A. Werner$^1$

Received: 4 January 2022 / Accepted: 19 February 2022 / Published online: 4 March 2022
© The Author(s) 2022

Abstract

Background  Labelled with lutetium-177, the urea-based small molecules PSMA I&T and PSMA-617 are the two agents most frequently used for radioligand therapy (RLT) in patients with advanced metastatic castration-resistant and prostate-specific membrane antigen (PSMA) expressing prostate cancer (mCRPC). In this matched-pair analysis, we aimed to compare the toxicity and efficacy of both agents for PSMA-directed RLT.

Materials and methods  A total of 110 mCRPC patients from two centres were accrued, 55 individuals treated with $^{[177}\text{Lu}]$Lu-PSMA I&T, and a matched cohort of 55 patients treated with $^{[177}\text{Lu}]$Lu-PSMA-617. Matching criteria included age at the first cycle, Gleason score, prostate-specific antigen (PSA) values, and previous taxane-based chemotherapy. Using common terminology criteria for adverse events (CTCAE v. 5.0), toxicity profiles were investigated (including bone marrow and renal toxicity). Overall survival (OS) between both groups was compared.

Results  Toxicity assessment revealed grade III anaemia in a single patient (1.8%) for $^{[177}\text{Lu}]$Lu-PSMA I&T and five (9.1%) for $^{[177}\text{Lu}]$Lu-PSMA-617. In addition, one (1.9%) grade III thrombopenia for $^{[177}\text{Lu}]$Lu-PSMA-617 was recorded. Apart from that, no other grade III/IV toxicities were present. A median OS of 12 months for patients treated with $^{[177}\text{Lu}]$Lu-PSMA I&T did not differ significantly when compared to patients treated with $^{[177}\text{Lu}]$Lu-PSMA-617 (median OS, 13 months; $P=0.89$).

Conclusion  In this matched-pair analysis of patients receiving one of the two agents most frequently applied for PSMA RLT, the rate of clinically relevant toxicities was low for both compounds. In addition, no relevant differences for OS were observed.

Keywords  PSMA I&T · PSMA-617 · Prostate-specific membrane antigen · Prostate cancer · Radioligand therapy · Matched pair

Introduction

As the second most frequent malignancy in men worldwide, the annual incidence of prostate cancer (PC) is 1.4 million and accounts for $>375,000$ deaths [1]. The transition from an androgen-dependent to a castration-resistant phenotype poses challenges for treating clinicians, especially in widespread diseases. Recent years have witnessed the introduction of novel therapeutic regimens for metastatic castration-resistant prostate cancer (mCRPC), including androgen receptor signalling inhibitors [2, 3] chemotherapeutics [4–6], and prostate-specific membrane antigen (PSMA)-directed radioligand therapies (RLT), which are typically carried out with small-molecule, urea-based agents linked to the $\beta$-emitting radionuclide lutetium-177 [7]. In this regard, recent prospective trials have shown remarkable outcomes after PSMA RLT in patients with mCRPC [8–11]. For instance, the VISION trial reported a substantial prolongation of overall survival (OS) when compared to current standard-of-care therapy, along with an objective response rate in approximately half of the patients [12].
To date, PSMA-targeted RLT is mainly conducted with the two different agents, $[^{177}\text{Lu}]$Lu-PSMA I&T and $[^{177}\text{Lu}]$Lu-PSMA-617 [7]. As shown in Fig. 1, the chemical structures of the two labelled peptides for PSMA-directed RLT show significant differences. Only the urea-binding motif of the two peptides is identical, but the majority of the two molecules show no structural similarity. On closer inspection, even the chelators are different: while in $[^{177}\text{Lu}]$Lu-PSMA-617, the peptide is linked to a DOTA chelator [13], in $[^{177}\text{Lu}]$Lu-PSMA I&T, the related DOTAGA chelator is used [14]. Of note, a recent dosimetry study reported on comparable mean absorbed tumour doses for both compounds [15]. In a preclinical setting, $[^{177}\text{Lu}]$Lu-PSMA-617 seems to be superior when compared to $[^{177}\text{Lu}]$Lu-PSMA I&T [16]. Head-to-head comparisons in patients, however, are still lacking [7]. In this two-centre, matched-pair analysis, we compared the toxicity and efficacy of $[^{177}\text{Lu}]$Lu-PSMA I&T and $[^{177}\text{Lu}]$Lu-PSMA-617 for treatment of patients with mCRPC.

**Materials and methods**

**Patient cohort**

This retrospective study consisted of 55 patients who were treated with $[^{177}\text{Lu}]$Lu-PSMA I&T for mCRPC at the University Hospital Würzburg (Germany) and received at least two cycles of RLT. The matched cohort included 55 patients with mCRPC treated with at least two cycles of $[^{177}\text{Lu}]$Lu-PSMA-617 at the University Hospital Bonn (Germany). Matching criteria included age at the first cycle, Gleason score (categories: 6–7, 8–10, or unknown, [17]), baseline PSA values (0–50 ng/mL, 50–200 ng/ml, 200–600 ng/ml, and > 600 ng/mL), and previous taxane-based chemotherapies (CTx). Approvals were waived by the local Ethics Committees of Bonn and Würzburg due to the retrospective nature of this analysis (20210422 04).

**Treatment protocol**

Standardized institutional protocols for the execution of RLT were applied. In-house labelling was carried out for...
[177Lu]-labelled PSMA ligands ([177Lu]Lu-PSMA I&T (Würzburg) and [177Lu]Lu-PSMA-617 (Bonn)). Radiosynthesis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 have been described elsewhere [18, 19]. Identical treatment protocols at both study sites included administration of approximately 6.0 GBq of the PSMA ligand every 8 weeks with up to a maximum of 8 cycles, depending on the response to treatment [18, 19].

Toxicity and efficacy assessment

Standard blood collection included prostate-specific antigen (PSA) values, leukocytes, haemoglobin, platelets, creatinine, lactate dehydrogenase, aspartate aminotransferase, gamma-glutamyltransferase, and alkaline phosphatase. By comparing with baseline parameters, toxicity was assessed at the last available cycle. Changes in blood cell counts and creatinine levels were also graded according to the Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) [20]. Efficacy was assessed by comparing OS between both cohorts.

Statistical analysis

Statistical analyses were performed using GraphPad Prism version 9.3.0 (GraphPad Software, San Diego, CA, USA). Descriptive data (including OS) are presented as median and range in parentheses. Since not all parameters were normally distributed (Shapiro–Wilk test), comparisons between the two cohorts were performed using Wilcoxon signed-rank test. For comparison of dichotomous variables, Fisher’s exact test was applied. OS was analysed using Kaplan–Meier curves and log-rank comparison. A P-value less than 0.05 was considered statistically significant.

Results

Patients’ characteristics were comparable for both cohorts Overall, the median patient age at the first cycle of therapy was 71 (46–84) years for [177Lu]Lu-PSMA I&T and 70 (43–86) years for [177Lu]Lu-PSMA-617. The median Gleason score was 9 in both cohorts. For baseline PSA levels, no significant differences between the groups were observed ([177Lu]Lu-PSMA I&T: 168.0 (5.0–3130) ng/ml, [177Lu]Lu-PSMA-617: 145 (3.6–2360) ng/ml; P = 0.16). In addition, serum chemistry, blood counts, and previous therapies also did not differ between both groups. For preexisting comorbidities, only arterial hypertension differed significantly between both groups ([177Lu]Lu-PSMA I&T: 56.4%, [177Lu]Lu-PSMA-617: 27.3%; P = 0.004). In total, patients received a median of three RLT cycles of either [177Lu]Lu-PSMA I&T or [177Lu]Lu-PSMA-617 (P = 0.77). As such, neither cumulative administered activity ([177Lu]Lu-PSMA I&T, 18.0 GBq; [177Lu]Lu-PSMA-617, 19.0 GBq), nor median activity per cycle ([177Lu]Lu-PSMA I&T, 6.0 GBq; [177Lu]Lu-PSMA-617, 6.2 GBq) differed significantly (P > 0.05, respectively; Table 1).

Toxicity profiles revealed no relevant differences between both agents During follow-up, patients treated with [177Lu]Lu-PSMA I&T demonstrated a median decrease of leukocytes, haemoglobin, and platelets of 11.6%, 6.3%, and 12.1%, respectively. For [177Lu]Lu-PSMA-617, comparable respective declines of 13.0%, 9.6%, and 12.8% were recorded. No significant difference was reached for a decrease between both agents. Creatinine levels increased slightly in both cohorts ([177Lu]Lu-PSMA I&T, 4.9%; [177Lu]Lu-PSMA-617, 4.2%; n.s.; Fig. 2). Compared to baseline, only one grade III anaemia (1.8%) was observed in the [177Lu]Lu-PSMA I&T cohort and five grade III anaemia (9.1%) in the [177Lu]Lu-PSMA-617 cohort. For the latter agent, there was also one grade III (1.9%) toxicity for platelets after the last cycle. Apart from that, no further grade III/IV toxicities were recorded for either agent (Fig. 3, Table 2).

Overall survival is also comparable for both agents Median OS was 12 months for patients treated with [177Lu]Lu-PSMA I&T and 13 months for patients treated with [177Lu]Lu-PSMA-617 (P = 0.89; Fig. 4).

Discussion

In this matched-pair analysis, we investigated the two most commonly applied urea-based, small-molecule inhibitors of PSMA, namely PSMA-617 and PSMA I&T. We carefully matched patients based on age, Gleason score, and PSA levels. Pre-therapeutic CTx has also been suggested to have a relevant impact on outcome [21] and, thus, we also matched according to this previous treatment regimen. After having controlled for such key variables, toxicity assessments revealed low rates of side effects, with one grade III anaemia for [177Lu]Lu-PSMA I&T and five grade III anaemia as well as one grade III thrombopenia for [177Lu]Lu-PSMA-617. Moreover, OS for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA I&T did not significantly differ.

Multiple prospective trials have reported a favourable outcome for [177Lu]Lu-PSMA-617, including prolonged OS when compared to standard-of-care [12], and pain reduction in patients with disease progression after conventional treatment [9]. As the second most commonly used RLT agent [7], [177Lu]Lu-PSMA I&T has been utilized in retrospective studies demonstrating beneficial outcomes in heavily pretreated mCRPC patients [22]. Results of a currently recruiting, a prospective clinical trial investigating the performance
of this agent as a last-line option will be announced in due course [23]. Despite the encouraging results for both radiopharmaceuticals, head-to-head comparisons are still scarce [7]. In this matched-pair analysis focusing on outcome and toxicity, respective Kaplan–Meier curves for OS revealed no significant differences between patients treated with $^{177}$Lu-PSMA I&T (median 12 months) and $^{177}$Lu-PSMA-617 (median 13 months). This is in line with a recent dosimetry study comparing both $^{177}$Lu-labelled, PSMA-directed small molecules. Although no matching was conducted, $^{177}$Lu-PSMA I&T had increased initial uptake in metastatic sites of disease, while the residency time and the effective half-life was longer for $^{177}$Lu-PSMA-617. Nonetheless, those findings had no relevant impact on the mean absorbed tumour doses ($^{177}$Lu-PSMA I&T: 5.8 Gy/GBq, $^{177}$Lu-PSMA-617: 5.9 Gy/GBq) [15], which may explain comparable outcome benefits for both agents observed in our study.

No grade III/IV renal toxicities occurred during follow-up. For hematotoxicity, we observed only one patient with new grade III anaemia for $^{177}$Lu-PSMA I&T and five patients with new grade III anaemia for $^{177}$Lu-PSMA-617. For $^{177}$Lu-PSMA-617, there was also one grade III toxicity for platelets. Apart from that, no further grade III/IV toxicities were recorded for either agent. Taken together, this study corroborates previous reports investigating side effects in patients treated with $^{177}$Lu-PSMA-617 [7, 10–12, 24] or $^{177}$Lu-PSMA I&T [25], which also reported promising safety profiles for both agents. As such, the treating physician can have certainty that both $^{177}$Lu

### Table 1 Baseline patient characteristics

|                         | $^{177}$Lu-PSMA I&T | $^{177}$Lu-PSMA-617 | P-value |
|-------------------------|----------------------|----------------------|---------|
| **Clinical variables**  |                       |                      |         |
| Age at first cycle of PSMA RLT (years)# | 71 (46–84) | 70 (43–86) | 0.89    |
| Time period between initial diagnosis and 1st RLT (months) | 64.0 (9–246) | 63 (4–241) | 0.37    |
| Treatment cycles per patient | 3 (2–8)    | 3 (2–8)    | 0.77    |
| Cumulative activity (GBq) | 18.0 (10.4–49.2) | 19.0 (7.9–45.8) | 0.21    |
| Activity per cycle (GBq) | 6.0 (3.9–6.8) | 6.2 (3.9–9.6) | 0.11    |
| Gleason score# | 9 (6–10) | 9 (6–10) | 1.0     |
| **Baseline laboratory values** |                       |                      |         |
| PSA (ng/ml)# | 168 (5.0–3130) | 145 (3.6–2360) | 0.16    |
| LDH (37 °C U/l) | 269 (118–1105) | 274 (147–2582) | 0.13    |
| Leukocytes (Tsd/µl) | 6.0 (2.7–15.3) | 6.4 (1.5–13.8) | 0.46    |
| Haemoglobin (g/dl) | 11.5 (8.2–16.1) | 11.6 (7.9–13.8) | 0.34    |
| Platelets (Tsd/µl) | 245.0 (76.0–590) | 226.0 (45.0–562) | 0.27    |
| Creatinine (mg/dl) | 0.92 (0.60–1.92) | 0.82 (0.48–2.12) | 0.08    |
| AST (37 °C U/l) | 28.0 (15.0–62.0) | 28.0 (14.0–114.0) | 0.70    |
| Gamma-GT (37 °C U/l) | 32.1 (12.8–307.1) | 33.0 (12.0–1130) | 0.48    |
| AP (37 °C U/l) | 130 (31.0–1499) | 139 (45.0–982) | 0.65    |
| **Previous Treatments (%)** |                       |                      |         |
| Radical prostatectomy | 40.0 | 41.8 | 1.0    |
| Primary radiation therapy to the prostate | 16.4 | 18.2 | 1.0    |
| Adjuvant radiation therapy | 21.8 | 14.6 | 0.46    |
| Salvage radiation therapy | 18.2 | 9.1 | 0.27    |
| Antihormonal treatment | 100 | 100 | 1.0    |
| Second generation antihormonal treatment (Abiraterone/Enzalutamide) | 90.9 | 89.1 | 1.0    |
| Chemotherapy# | 72.4 | 72.4 | 1.0    |
| **Comorbidities (%)** |                       |                      |         |
| Arterial hypertension | 56.4 | 27.3 | 0.004    |
| Preexisting renal disease | 18.2 | 9.1 | 0.27    |
| Diabetes mellitus | 16.4 | 3.6 | 0.05    |

Abbreviations: PSA, prostate specific antigen; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; Gamma-GT, gamma-glutamyltransferase; AP, alkaline phosphatase

# = matching criteria
Lu-PSMA-617 and $[^{177}\text{Lu}]$ Lu-PSMA I&T achieve equivalent outcome benefits along with comparable low toxicity profiles.

For PSMA RLT, the structures of the two labelled peptides show relevant differences (Fig. 1) [13, 14]. Furthermore, murine studies performing head-to-head comparisons...
with both radiotracers demonstrated more favourable biodistribution for \([^{177}\text{Lu}]\text{Lu-PSMA-617}\) [16]. In light of these preclinical findings and the structural variances among both agents, the similar efficacy and toxicity of the two radiopharmaceuticals were not necessarily expected.

This study has limitations. Striving for an accurate matching, and despite including a total of 110 mCRPC patients, the sample size was rather small. The grouping of patients by original Gleason score categories (i.e. Gleason 6–7 and Gleason 8–10) allowed for adequate matching [17]. Nevertheless, future studies are needed to compare both agents in an even more controlled environment, preferably in a prospective setting. In this regard, such efforts may then adjust for further important variables, including dosimetry aspects, biodistribution, radiotracer preparation, and logistics. Moreover, compared to the VISION trial, which reported on an OS of 15.3 months for \([^{177}\text{Lu}]\text{Lu-PSMA-617}\) after a median of five cycles of RLT [12], our patients underwent only three cycles of treatment, thereby explaining our shorter OS of only 13 months for this agent. As such, we did not follow current treatment standards as defined by the VISION trial, and future studies should also include patients with a higher number of cycles [12].

### Conclusions

Investigating the most commonly used agents for PSMA-targeted RLT, \([^{177}\text{Lu}]\text{Lu-PSMA I&T}\) and \([^{177}\text{Lu}]\text{Lu-PSMA-617}\), this matched-pair analysis demonstrates that toxicity profiles of both compounds are comparable, with very low rates of clinically relevant toxicities. In addition, both radiopharmaceuticals are similarly effective in patients with mCRPC.
Author contribution  Conceptualization: P.E.H., R.A.W., R.A.B., and A.K.B.; methodology: F.X.W.; software: F.X.W.; validation: P.E.H., R.A.W., and R.A.B.; formal analysis: P.E.H., F.X.W., and R.A.B.; investigation: P.E.H., R.A.B., and F.X.W.; resources: A.K.B. and M.E.; data curation: P.E.H. and F.X.W.; writing—original draft preparation: P.E.H., R.A.W., and R.A.B.; writing—review and editing: R.A.W., R.A.B., A.K.B., A.S., A.K.S., M.E., H.K., S.P.R., and T.H.; visualization: F.X.W. and P.E.H.; supervision: R.A.W. and R.A.B.; project administration: P.E.H., R.A.W., A.K.B., and R.A.B.; funding acquisition: P.E.H. and T.H. All authors have read and agreed to the published version of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by the IZKF Wuerzburg (grant Z-02/85 to P.E.H.).

Data availability Detailed information about the image analysis or the overall survivals of the subjects presented in this study is available on reasonable request from the corresponding author.

Declarations

Institutional Review Board statement The study was conducted according to the guidelines of the Declaration of Helsinki. Ethical review and approval were waived for this study by the local Ethics Committee due to the retrospective character of the study (# 20210422 04).

Consent to participate All procedures have been conducted as part of clinical routine care. Informed consent has been obtained from all subjects.

Conflict of interest R.A.B. is a consultant for Bayer Healthcare (Leverkusen, Germany) and Eisai GmbH (Frankfurt, Germany). R.A.B. has a noncommercial research agreement and is on the speakers’ list of Mediso Medical Imaging (Budapest, Hungary). M.E. is a consultant for Bayer Healthcare (Leverkusen, Germany), Eisai GmbH (Frankfurt, Germany), IPSEN, and Novartis.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

2. Ryan CJ, Smith MR, de Bonis JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48. https://doi.org/10.1056/NEJMoA1209096.

3. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. https://doi.org/10.1056/NEJMoA1405095.

4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. https://doi.org/10.1056/NEJMoA040720.

5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26:242–5. https://doi.org/10.1200/jco.2007.12.4008.

6. de Bonis JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Koch I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England). 2010;376:1147–54. https://doi.org/10.1016/s0140-6736(10)61389-x.

7. Sadaghiani MS, Sheikhbabaie S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80:82–94. https://doi.org/10.1016/j.eururo.2021.03.004.

8. Calais J, Gafita A, Eiber MR, Armstrong WR, Gartmann J, Thin P, et al. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.261982.

9. Hofman MS, Violet J, Hicks RJ, Ferdinands J, Thang SP, Akhurst T, et al. ([177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33. https://doi.org/10.1016/s1470-2045(18)30198-0.

10. Violet J, Sandhu S, Irvani A, Ferdinands J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase ii prospective trial of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61:857–65. https://doi.org/10.2967/jnumed.119.236414.

11. Hofman MS, Emmett L, Sandhu S, Irvani A, Joshua AM, Goh JC, et al. ([177]Lu)Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet (London, England). 2021;397:797–804. https://doi.org/10.1016/s0140-6736(21)00237-3.

12. Sartor O, de Bonis J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103. https://doi.org/10.1056/NEJMoA2107322.

13. Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kra- tochwil C, Mier W, et al. Preclinical evaluation of a tailor-made dota-conjugated psma inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20. https://doi.org/10.2967/jnumed.114.147413.

14. Wei neisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Bey kan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. https://doi.org/10.2967/jnumed.115.158550.
15. Schuchardt C, Zhang J, Kulkarni HR, Chen X, Mueller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.121.262713.

16. Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339–50. https://doi.org/10.1007/s00259-020-05057-6.

17. Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:479–505. https://doi.org/10.6004/jnccn.2019.0023.

18. Yordanova A, Linden P, Hauser S, Meisenheimer M, Kurpig S, Feldmann G, et al. Outcome and safety of rechallenge with [177]Lu-Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1073–80. https://doi.org/10.1007/s00259-018-4222-x.

19. Hartrampf PE, Weinzierl F-X, Serfling SE, Pomper MG, Rowe SP, Higuchi T, et al. Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radionuclide therapy with [177]Lu-Lu-PSMA I&T. Cancers. 2022.

20. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES; 2017.

21. Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bügemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177]Lu-Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113–22. https://doi.org/10.1007/s00259-020-04797-9.

22. Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Salvage radiopeptide therapy of advanced castrate-resistant prostate cancer with lutetium-177-labeled prostate-specific membrane antigen: efficacy and safety in routine practice. Cancer Biother Radiopharm. 2018;33:274–81. https://doi.org/10.1089/cbr.2017.2403.

23. Prive BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, de Groot M, et al. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer. 2020;20:884. https://doi.org/10.1186/s12885-020-07386-z.

24. Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using [177]Lu-Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1473–9. https://doi.org/10.1007/s00259-017-3681-9.

25. Heck MM, Tauber R, Schweizer S, Retz M, D’ Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920–6. https://doi.org/10.1016/j.eururo.2018.11.016.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Philipp E. Hartrampf1 · Franz-Xaver Weinzierl1 · Andreas K. Buck1 · Steven P. Rowe2 · Takahiro Higuchi1 · Anna Katharina Seitz3 · Hubert Kübler3 · Andreas Schirbel1 · Markus Essler4 · Ralph A. Bundschuh4 · Rudolf A. Werner1

Franz-Xaver Weinzierl
franz-xaver.weinzierl@stud-mail.uni-wuerzburg.de
Andreas K. Buck
buck_a@ukw.de
Steven P. Rowe
srowe8@jhmi.edu
Takahiro Higuchi
thiguchi@me.com
Anna Katharina Seitz
seitz_a3@ukw.de
Hubert Kübler
kuebler_h@ukw.de
Andreas Schirbel
schirbel_a@ukw.de
Markus Essler
markus.essler@ukbonn.de
Ralph A. Bundschuh
ralph.bundschuh@ukbonn.de
Rudolf A. Werner
werner_r1@ukw.de

1 Department of Nuclear Medicine, University Hospital Wuerzburg, Oberdürricherstraße 6, 97080 Würzburg, Germany
2 Department of Radiology and Radiological Science, The Russell H Morgan, Johns Hopkins University School of Medicine, 601 N Caroline Str, Baltimore, MD, USA
3 Department of Urology and Paediatric Urology, University Hospital Wuerzburg, Oberdürricherstraße 6, 97080 Würzburg, Germany
4 Department of Nuclear Medicine, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany